Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants.

Antiviral research - 1 Feb 2024

Chou Sunwen, Watanabe Justin

Abstract excerpt

Therapeutic use of maribavir for human cytomegalovirus infection has renewed attention to the extent of cross-resistance with ganciclovir as the existing standard therapy. Each drug selects in vivo for a characteristic set of resistance mutations in the viral UL97 kinase gene. To improve the calibration of relative susceptibilities to each drug, genetic variants at relevant UL97 codons were extensively phenotyped...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Codon
Share to Cytomegalovirus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to Ganciclovir

Share to Mutation

Share to Phosphotransferases (Alcohol Group Acceptor)

Source

Open in PubMed Open full text

Identifiers

PMID: 38163624
DOI: 10.1016/j.antiviral.2023.105792
PMCID: PMC10922325

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants.PMID 38163624Read ↗

Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infectionSemantic proximity Read ↗

Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavirSemantic proximity Read ↗

Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection.Semantic proximity Read ↗

Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir ResistanceSemantic proximity Read ↗

Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance.Semantic proximity Read ↗

Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.Semantic proximity Read ↗

Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir.Semantic proximity Read ↗

Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II MutantSemantic proximity Read ↗

Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet.Semantic proximity Read ↗

The emergence of letermovir and maribavir drug-resistant mutations: from clinical trials to real-world studies.Semantic proximity Read ↗

Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance.Semantic proximity Read ↗

Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.